NCT06416735

Natriuretic Effect of Amiloride in Relation to the Alpha Adducin Gene (ADD-AMI) RS4961 Variant

Natriruetic Effect of Amiloride in Relation to the Alpha Adducin Gene (ADD-AMI) RS4961 Variant

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Ospedale San Raffaele · Academic / Other
• Sex: Male
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The study is a non-pharmacological interventional, single-center, national, non-randomised, comparative and open label.

Detailed description

The study is carried out to evaluate primarily the difference in the activity of the renal transporter ENaC (through dosage of sodium) through its inhibition with a single dose of Amiloride in hypertensive patients characterized by the polymorphism of alpha Adducin rs496. It's also aimed to see the difference in potassium and the change in systolic and diastolic blood pressure after amiloride administration

Conditions

• Hypertension Essential
• Salt Excess
• Genetic Hypertension

Interventions

Type	Name	Description
DRUG	Amiloride	administration of a single dose of 5 or 10 mg of Amiloride (based on body weight) After oral intake of the drug, the increase in sodium in the urine ends within 8 hours

Timeline

• Start date: 2018-09-28
• Primary completion: 2020-07-20
• Completion: 2020-07-20
• First posted: 2024-05-16
• Last updated: 2024-05-16

Locations

1 site across 1 country: Italy

Regulatory

• FDA-regulated drug study